已发表论文

瑞马唑仑联合瑞芬太尼用于减轻老年女性患者喉罩置入时应激反应的剂量反应研究:一项前瞻性双盲研究

 

Authors Xu Q, Qian J, Zhang SQ, Xia F, Hu HJ, Xiao F 

Received 3 September 2024

Accepted for publication 11 February 2025

Published 5 March 2025 Volume 2025:19 Pages 1575—1583

DOI https://doi.org/10.2147/DDDT.S494426

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Qiongyu Guo

Qiang Xu,* Jing Qian,* Su-Qin Zhang, Feng Xia, Hui-Jing Hu, Fei Xiao

Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing City, Zhejiang Province, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hui-Jing Hu; Fei Xiao, Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, East Zhonghuang Road, Jiaxing City, People’s Republic of China, Tel +86 573 83963131-8300, Email hhj08mz@163.com; 13706597501@163.com

Background: Optimum dose of remimazolam for inducing loss of consciousness in elderly patients has been suggested by prior studies. Opioids can enhance their sedative effects, thereby permitting dose reduction. However, the dose-response of remimazolam when combined remifentanil for attenuating stress response during laryngeal mask airway (LMA) insertion in elderly female patients is still unknown. Moreover, the ideal dose of medications is especially critical in elderly patients due to their compromised cardiopulmonary function. The objective of this study was to determine the median effective dose (ED50) and ED95 of remimazolam in inhibiting the stress response associated with LMA insertion.
Methods: Sixty aged ≥ 65 and < 80 years old female patients were randomized allocated into 1 of 4 groups receiving doses of 0.2, 0.25, 0.3, and 0.35 mg/kg remimazolam. Following a dosage of 2.0 ng/mL of remifentanil, patients received different doses of remimazolam. Effective dose is defined as the prevention of stress response associated with LMA insertion, characterized by a post-sedation induction SBP variation < 20% of baseline value, jaw relaxation and absence of patient body motion during the initial 2 minutes following LMA insertion. Probit regression analysis was utilized to estimate the ED50 and ED90 values.
Results: The ED50 and ED95 of effective remimazolam of general induction for elderly female patients not suffer intubation stress response were 0.24 mg/kg (95% CI 0.20– 0.27 mg/kg) and 0.37 mg/kg (95% CI 0.32– 0.49 mg/kg), respectively. The incidence of hypotension was 33.3% (5/15), 46.7% (7/15), 73.3% (11/15), and 80% (12/15) in the four groups, respectively.
Conclusion: The ED50 and ED95 values of intravenous remimazolam for preventing stress response during LMA insertion were 0.24 and 0.37 mg/kg, respectively in elderly female.
Trial Number and Registry Url: Registration number, ChiCTR2400083990, https://www.chictr.org.cn/showproj.html?proj=229006.

Keywords: remimazolam, remifentanil, dose-response, stress response, elderly patients